World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
56
Citations
23492
World Ranking
3652
National Ranking
321

Gary Dubin publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Gary Dubin sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 98 publications — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Gary Dubin D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Gary Dubin sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 56 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Gary Dubin is affiliated with GlaxoSmithKline in the United Kingdom and conducts research primarily in the field of medicine. Their work spans multiple subfields, including epidemiology, animal science and zoology, public health, environmental and occupational health, infectious diseases, and surgery.

The research topics covered by Dubin focus extensively on cervical cancer and HPV research, hepatitis B virus studies, animal virus infections studies, mosquito-borne diseases and control, viral infections and vectors, virology and viral diseases, and genital health and disease.

Dubin has contributed to multiple publications, with recent papers appearing in respected venues. These include:

  • Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied, 2020, The Journal of Infectious Diseases
  • Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection, 2022, The Journal of Infectious Diseases
  • Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative study, 2020, EClinicalMedicine
  • Efficacy Results of a Trial of a Herpes Simplex Vaccine, 2020, UNC Libraries

Frequent co-authors who have collaborated with Dubin include:

  • Simopekka Vänskä
  • Tapio Luostarinen
  • Iacopo Baussano
  • Dan Apter
  • Tiina Eriksson

Dubin's publications are often found in journals such as The Journal of Infectious Diseases, EClinicalMedicine, and UNC Libraries.

Best Publications

  • Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

    Diane M. Harper;Eduardo L. Franco;Cosette Wheeler;Daron Gale Ferris

  • Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

    J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler

  • Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

    Diane M Harper;Eduardo L Franco;Cosette M Wheeler;Anna-Barbara Moscicki

  • Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

    Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud

  • Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

    Lawrence R. Stanberry;Spotswood L. Spruance;Anthony L. Cunningham;David I. Bernstein

  • Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

    Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn

  • ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

    J. Abramson;L. Pickering;Janet Gilsdorf

  • Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

    Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

  • Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

    Sandra L Giannini;Emmanuel Hanon;Philippe Moris;Marcelle Van Mechelen

  • Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

    Cosette M. Wheeler;Xavier Castellsagué;Suzanne M. Garland;Anne Szarewski

  • Efficacy Results of a Trial of a Herpes Simplex Vaccine

    Robert B. Belshe;Peter A. Leone;David I. Bernstein;Anna Wald

  • Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

    Mark H. Einstein;Mira Baron;Myron J. Levin;Archana Chatterjee

  • Serum antibody responses after intradermal vaccination against influenza.

    Robert B. Belshe;Frances K. Newman;Joan Cannon;Carol Duane

  • Epidemiology, clinical presentation and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women

    David I. Bernstein;Abbie R. Bellamy;Edward W. Hook;Myron J. Levin

  • Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial

    Diane M. Harper;Eduardo L. Franco;Cosette Wheeler;Daron G. Ferris

  • Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

    Romanowski B;de Borba Pc;Naud Ps

  • Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

    Aimée R Kreimer;Frank Struyf;Maria Rowena Del Rosario-Raymundo;Allan Hildesheim

  • Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant

    Court Pedersen;Tiina Petaja;Gitte Strauss;Hans C. Rumke

  • Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.

    Dominique Descamps;Karin Hardt;Bart Spiessens;Patricia Izurieta

  • Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

    S. Rachel Skinner;S. Rachel Skinner;Anne Szarewski;Barbara Romanowski;Suzanne M. Garland

  • Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection

    Allan Hildesheim;Rolando Herrero;Sholom Wacholder;Ana C. Rodriguez

Frequent Co-Authors

Matti Lehtinen
Matti Lehtinen Tampere University
Suzanne M. Garland
Suzanne M. Garland University of Melbourne
Jorma Paavonen
Jorma Paavonen University of Helsinki
Cosette M. Wheeler
Cosette M. Wheeler University of New Mexico
Xavier Castellsagué
Xavier Castellsagué University of Barcelona
Bruce L. Innis
Bruce L. Innis GlaxoSmithKline (United Kingdom)
Henry C Kitchener
Henry C Kitchener University of Manchester
Myron J. Levin
Myron J. Levin University of Colorado Anschutz Medical Campus
F. Xavier Bosch
F. Xavier Bosch Open University of Catalonia
Wim Quint
Wim Quint Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Microbiology opens doors to various related career paths and online programs. For those interested in public health, exploring the easiest mph online programs to get into can be a strategic way to advance in the healthcare field without the added pressure of extremely competitive admissions.

Another rewarding career path that aligns with the foundations of microbiology is becoming a Child Life Specialist. Understanding child development and healthcare in clinical settings can be enhanced through specialized training, and learning about child.life specialist salary expectations can help guide career choices.

For individuals facing challenges such as a criminal record, there are still accessible opportunities available. Some of the college degrees for felons include online programs that promote inclusivity and second chances in education and career development.

Additionally, combining microbiological knowledge with healthcare practice can lead to roles like a Functional Medicine Nurse Practitioner. This career requires specialized education, so reviewing the pathway on functional medicine nurse practitioner can offer valuable insights into this growing field.

Best Scientists Citing Gary Dubin

Trending Scientists

Recently Published Articles